RetinaCME
EXPERT VIDEOCMEABO MOC

Current Undertreatment of Patients With nAMD – Defining the Need for More Flexible Dosing

Author(s)/Faculty: Arshad M. Khanani, MD, MA; Sophie J. Bakri, MD
Release Date: 7/23/2020Expiration Date: 7/22/2021
Credit Type: CME / ABO MOCNumber of Credits: 0.25
Content Type: VideoProvider:
Pinnacle clinical trials evaluating anti–vascular endothelial growth factor (VEGF) therapies in management protocols for neovascular age-related macular degeneration (nAMD) have demonstrated significant visual acuity gains, yet these same benefits are not always reflected in real-world patient analyses. These discrepancies can be associated with undertreatment of patients with nAMD and lack of patient adherence due to treatment burden. Therapeutic agents and dosing strategies designed to overcome treatment burden by elongating time between dosing intervals are evolving and have the potential to enhance visual outcomes in patients with nAMD when integrated into clinical practice. In this curbside consult, Dr. Arshad Khanani and Dr. Sophie Bakri discuss the current undertreatment of patients with nAMD and illustrate the need for more flexible dosing.